Search

Your search keyword '"Rozentale B."' showing total 99 results

Search Constraints

Start Over You searched for: Author "Rozentale B." Remove constraint Author: "Rozentale B."
99 results on '"Rozentale B."'

Search Results

51. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

52. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

53. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

54. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

55. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

56. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

57. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study

58. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

59. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

60. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

62. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

63. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

64. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

65. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

66. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

67. Dialysis and renal transplantation in HIV-infected patients: a European survey

68. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

69. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens.

70. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

71. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

79. Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy

80. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

83. HIV drug resistance tendencies in Latvia.

84. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

85. Genomic and phenotypic inconsistencies in Pseudomonas aeruginosa resistome among intensive care patients.

86. HLA class II DRB1, DQA1, DQB1 loci in patients with HIV infection and tuberculosis in a Latvian cohort group.

87. Hepatitis A virus subgenotypes in Latvia, 2008-2021.

88. Amino Acid Metabolism is Significantly Altered at the Time of Admission in Hospital for Severe COVID-19 Patients: Findings from Longitudinal Targeted Metabolomics Analysis.

90. Intriguing findings of liver fibrosis following COVID-19.

92. Genetic variation spectrum in ATP7B gene identified in Latvian patients with Wilson disease.

93. Phylogenetic analysis of the Latvian HIV-1 epidemic.

94. Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia.

95. The prevalence of viral hepatitis C in Latvia: a population-based study.

96. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia.

97. From clinical and biochemical to molecular genetic diagnosis of Wilson disease in Latvia.

98. Quality control assessment for the serological diagnosis of tick borne encephalitis virus infections.

99. Rapid epidemic spread of HIV type 1 subtype A1 among intravenous drug users in Latvia and slower spread of subtype B among other risk groups.

Catalog

Books, media, physical & digital resources